Radnet AI Stock Analysis
Want to see RDNT full AI Analyst Report?
Radnet (RDNT) AI Stock Analysis
Radnet
(NASDAQ:RDNT)
The score is held back primarily by weaker financial performance (net losses, thin margins, high leverage, and negative TTM free cash flow). Offsetting this, the latest earnings call was notably constructive with raised guidance, strong liquidity, and visible growth drivers, and technicals also show a supportive uptrend. Valuation remains a modest negative given the loss-driven negative P/E and lack of dividend support.
Radnet (RDNT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $5.90B
- Dividend Yield
- ―
- Average Volume (3M)
- 677.81K
- Price to Earnings (P/E)
- -261.6
- Beta (1Y)
- 0.98
- Revenue Growth
- 21.06%
- EPS Growth
- -70.26%
- Country
- US
- Employees
- 9,060
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Radnet Business Overview & Revenue Model
Company Description
RadNet, Inc. operates as a prominent healthcare services company specializing in outpatient diagnostic imaging across the United States. Their comprehensive offerings span a broad spectrum of advanced imaging techniques, including magnetic resonance...
How the Company Makes Money
RadNet primarily makes money by performing diagnostic imaging exams at its outpatient imaging centers and getting paid for those services. Revenue is generally generated on a per-procedure basis and is largely reimbursed by third-party payors (includ...
Radnet Earnings Call Summary
The call was strongly positive. RadNet reported record company revenue and adjusted EBITDA, broad-based imaging volume growth, expanding advanced-imaging mix, raised Imaging Center and Digital Health guidance, strong liquidity, substantial Digital Health bookings and ARR growth, and continued progress in AI deployment and the planned ONRAD acquisition. The main challenges were year-over-year Digital Health EBITDA and margin declines, labor shortages, implementation seasonality and constraints, and expected 2027 Medicare reimbursement pressure, but management characterized the implementation constraints as resolved and remained confident about fourth-quarter and 2027 growth.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, Imaging Center segment total net revenue guidance is $2.385 billion to $2.435 billion, adjusted EBITDA guidance is $350 million to $363 million, capital expenditure guidance is $170 million to $180 million, and free cash flow guidance is $120 million to $130 million; Digital Health revenue guidance is $135 million to $145 million, while adjusted EBITDA guidance is $10 million to $13 million and adjusted EBITDA before noncapitalized R&D guidance is $11 million to $13 million, with Digital Health CapEx guidance increased by $1 million. Digital Health is on track for more than $140 million of ARR by year-end, roughly 87% growth over 2025, expects fourth quarter revenue to grow about 20% sequentially, and indicated a fully underpinned fourth quarter of well above $40 million; ONRAD is expected to add $190 million to $200 million of revenue and $60 million to $65 million of adjusted EBITDA in its first year of operation after closing. For 2027, RadNet estimated an approximately $5 million revenue impact from the final Medicare rule, while noting Congress may act to partially or fully reverse this reduction.
Radnet Financial Statement Overview
Summary
Strong revenue growth and solid operating cash flow are outweighed by thin/compressing margins, recent net losses, elevated leverage (debt-to-equity ~1.94x), and a swing to negative TTM free cash flow (-$155M), which limits financial flexibility despite improving scale.
Income Statement
44NeutralBalance Sheet
46NeutralCash Flow
41Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.38B | 2.04B | 1.83B | 1.62B | 1.43B | 1.32B |
| Gross Profit | 233.49M | 90.80M | 249.12M | 221.39M | 165.72M | 191.80M |
| EBITDA | 295.20M | 253.95M | 262.55M | 292.79M | 278.53M | 278.37M |
| Net Income | -22.38M | -18.65M | 2.79M | 3.04M | 10.65M | 24.73M |
Balance Sheet | ||||||
| Total Assets | 4.28B | 3.76B | 3.29B | 2.69B | 2.43B | 2.06B |
| Cash, Cash Equivalents and Short-Term Investments | 750.61M | 767.22M | 740.02M | 342.57M | 127.83M | 134.61M |
| Total Debt | 2.17B | 1.86B | 1.73B | 1.49B | 1.51B | 1.40B |
| Total Liabilities | 2.84B | 2.40B | 2.15B | 1.88B | 1.94B | 1.71B |
| Stockholders Equity | 1.12B | 1.09B | 902.31M | 630.70M | 333.00M | 228.90M |
Cash Flow | ||||||
| Free Cash Flow | -155.28M | 85.57M | 44.95M | 44.26M | -103.00M | -71.20M |
| Operating Cash Flow | 341.47M | 298.82M | 233.02M | 220.86M | 146.42M | 149.49M |
| Investing Cash Flow | -601.56M | -343.87M | -233.07M | -201.47M | -246.95M | -221.51M |
| Financing Cash Flow | 207.97M | 72.21M | 397.95M | 195.63M | 93.65M | 104.67M |
Radnet Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDNT, the sentiment is Positive. The current price of 74.92 is above the 20-day moving average (MA) of 74.63, above the 50-day MA of 72.90, and above the 200-day MA of 65.43, indicating a bullish trend. The MACD of 1.38 indicates Positive momentum. The RSI at 51.31 is Neutral, neither overbought nor oversold. The STOCH value of 38.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RDNT.
Radnet Risk Analysis
Radnet disclosed 48 risk factors in its most recent earnings report. Radnet reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksRadnet Peers Comparison
Overall Rating
DGX76Outperform
LH75Outperform
RDNT57Neutral
NEO54Neutral
OPK52Neutral
NDRA42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | $28.20B | 25.20 | 15.21% | 1.32% | 9.13% | 17.93% | |
| 75Outperform | $29.90B | 30.09 | 11.54% | 0.78% | 6.02% | 19.63% | |
| 57Neutral | $5.90B | -261.64 | -2.04% | ― | 21.06% | -70.26% | |
| 54Neutral | $1.97B | -61.65 | -3.97% | ― | 11.08% | 71.76% | |
| 52Neutral | $1.20B | -8.41 | -12.41% | ― | -21.87% | 18.50% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | $5.88M | -0.62 | -224.80% | ― | ― | 60.87% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| RDNT | Radnet | 74.92 | -5.37 | -6.69% | |
| LH | Labcorp Holdings Inc. | 368.24 | 110.30 | 42.76% | |
| OPK | Opko Health | 1.62 | 0.31 | 23.66% | |
| DGX | Quest Diagnostics | 256.35 | 73.47 | 40.17% | |
| NEO | NeoGenomics Inc. | 15.25 | 4.97 | 48.35% | |
| NDRA | Endra Life Sciences | 3.92 | -2.73 | -41.05% |
Radnet Corporate Events
RadNet to Acquire ONRAD, Expanding Radiology Services Platform
PositiveOn October 26, 2026, RadNet entered into a definitive agreement to acquire ONRAD, Inc., in a cash‑and‑stock deal worth $350 million in cash plus five million RadNet shares at closing, with a potential earn‑out of up to $210 million tied to ONRAD’s 20...
RadNet Registers Shares for See-Mode Milestone Resale
NeutralOn August 14, 2026, RadNet, Inc. filed a prospectus supplement with the Securities and Exchange Commission to register for resale up to 34,069 shares of its common stock held by certain See-Mode Sellers. These shares will be issued as part of the sha...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
